Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.
  • TickerAPTX
  • ISINUS03836N1037
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

Jonathan Moreland

InsiderInsights Weekly Tables: January 18, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Laura Chico

Starting the New Year Off Right - APTX Tops Off Balance Sheet

Jonathan Moreland

InsiderInsights Daily Ratings Report: January 16, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Weekly Tables: January 18, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Laura Chico

Starting the New Year Off Right - APTX Tops Off Balance Sheet

Jonathan Moreland

InsiderInsights Daily Ratings Report: January 16, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: January 14, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ValuEngine Rating and Forecast Report for APTX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch